1. Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
- Author
-
Jörimann L, Tschumi J, Zeeb M, Leemann C, Schenkel CD, Neumann K, Chaudron SE, Zaheri M, Frischknecht P, Neuner-Jehle N, Kuster H, Braun DL, Grube C, Kouyos R, Metzner KJ, and Günthard HF
- Subjects
- Humans, Proviruses genetics, Leukocytes, Mononuclear, Viral Load, HIV-1 genetics, HIV Infections drug therapy
- Abstract
Human immunodeficiency virus type 1 (HIV-1) infection is treated with antiretroviral therapy (ART), usually consisting of 2-3 different drugs, referred to as combination ART (cART). Our recent randomized clinical trial comparing a switch to dolutegravir monotherapy with continuation of cART in early-treated individuals demonstrated sustained virological suppression over 48 weeks. Here, we characterize the longitudinal landscape of the HIV-1 reservoir in these participants, with particular attention to potential differences between treatment groups regarding evidence of evolution as a proxy for low-level replication. Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs). Neither an increase in genetic distance nor diversity over time was detected in participants of both treatment groups. Single proviral analysis showed high proportions of defective proviruses and low DRM numbers. No evidence for evolution during dolutegravir monotherapy was found in these early-treated individuals., Competing Interests: Potential conflicts of interest. D. L. B. reports honoraria for advisory boards from Gilead, Merck, and ViiV, outside the present work. K. J. M. has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, GlaxoSmithKline, Merck Sharp & Dohme, Bristol Myers Squibb, ViiV, and Abbott, and has received advisory board honoraria from Gilead Sciences and ViiV. The University of Zurich received research grants from Gilead Sciences, Novartis, Roche, and Merck Sharp & Dohme for studies for which K. J. M. serves as principal investigator. H. F. G. has received grants from the SNF, Swiss HIV Cohort Study, Yvonne Jacob Foundation, University of Zurich's Clinical Research Priority Program, Zurich Primary HIV Infection, Systems.X, NIH, Gilead Sciences, and Roche; personal fees from Merck, Gilead Sciences, ViiV, Janssen, GSK, Johnson & Johnson, and Novartis for consultancy or data and safety monitoring board membership; and a travel grant from Gilead. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF